Abstract:e14609 Background: ICI rechallenge after irAE has become a significant clinical dilemma, with irAE recurrence rates of 30-40% after rechallenge. Here we examine factors influencing ICI rechallenge rates across a 10-year period at the Massachusetts General Hospital (MGH), where the Severe Immunotherapy Complications service is available to provide multidisciplinary irAE expertise. Methods: We included patients admitted to MGH for an irAE from August 2011 to July 2023. We collected baseline demographics, ICI regimens, and irAE features. The choice of ICI used at rechallenge was grouped into 3 categories: 1) restarting an ICI within the same class, 2) switching classes (CTLA-4 to PD-(L)1 or vice versa), or 3) de-escalating from combination to monotherapy. Chi-square and Mann-Whitney U tests were applied to descriptive statistics. Results: Among 5882 patients treated with ICI, 671 (11.4%) patients were admitted for irAE. The median age was 67.6 (IQR, 59-74.9) years and 58% were male. Initial ICI regimens consisted of anti-PD-(L)1 (64.8%), anti-CTLA4 (10.9%), and ICI combinations (24.3%). 174 of 671 patients (25.9%) were rechallenged after an irAE requiring hospitalization. Rechallenge was common after rheumatologic, endocrine, dermatologic irAE and GI irAE, but rare after cardiac, neurologic, or pulmonary irAE (Table 1). The median time to rechallenge was 25 days (IQR 18-91) after endocrine irAE and 72 days (IQR 40-209) after non-endocrine irAE (p<0.001). Rechallenge was more common in melanoma (35%, p<0.001), and less common in lung (13.6%, p<0.001) and GU cancers (10%, p=0.003). Rechallenge rates were significantly higher in patients initially on combination therapy (39.6%) versus PD-(L)1 monotherapy (15.5%), p<0.001. Of those rechallenged, 43.2% initially on combination therapy were de-escalated to monotherapy and 53% were restarted within the same class. Amongst the PD-(L)1 monotherapy group, 88.4% were restarted within the same class and 11.6% switched classes. Conclusions: Here we examine practice patterns at a large academic center, where 25.9% of patients with irAE requiring hospitalization were rechallenged. Rechallenge was more prevalent in patients with melanoma or on ICI combination therapy, whereas it was less frequent following cardiac, neurologic, or pulmonary irAE. Under adequate risk-benefit evaluation, close monitoring, and multidisciplinary care, ICI rechallenge can be considered. [Table: see text]

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis

Pembrolizumab-Induced Myasthenia Gravis With Myocarditis in the Setting of Metastatic Renal Cell Carcinoma

Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review

Ncmp-28. Case Report: Refractory Myasthenia Gravis Flare Induced By Immune Check Point Inhibitor

Case of Immune Checkpoint Inhibitor Induced Myasthenia Gravis

Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors

Abstract 4144219: Safety and Efficacy of Rechallenging Immune Checkpoint Inhibitors after Discontinuation Due to Immune-Associated Myocarditis in Cancer Patients

Myasthenia gravis and myocarditis induced by chemoimmunotherapy in locally advanced gastric cancer: A case report

Case report: A successful re-challenge report of GLS-010 (Zimberelimab), a novel fully humanized mAb to PD-1, in a case of recurrent endometrial cancer

Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.

Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review

Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study

Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report

Acetylcholine receptor binding antibody–associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review

Novel uses of complement inhibitors in myasthenia gravis—Two case reports

Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis

Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced esophageal squamous cell cancer: A case report

Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions

A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma

Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study

Immune checkpoint-mediated myositis and myasthenia gravis: A case report and review of evaluation and management